Enlivex Pharmaceuticals raises $21 million for Rain prediction market token fund

Enlivex Immunotherapy Company raises $21 million through a debt agreement to expand its crypto asset accumulation strategy, focusing on the RAIN token of the Rain prediction platform. The company spent $10 million to purchase an additional 3 billion RAIN tokens at a 62% discount, while also extending the option to buy an additional 272.1 billion tokens until December 2027. The funds come from asset management firm The Lind Partners.

Meanwhile, Enlivex also approved a $20 million share buyback program to increase shareholder value. Rain's model incorporates a 2.5% fee mechanism used for token buybacks and burns, supporting supply and demand incentives.

Following this news, RAIN slightly increased to $0.009 before adjusting, while ENVL shares showed no significant movement. Investment trends in the prediction market are surging, with industry-wide trading volume increasing over 1,200% in a year.